A.G.P./Alliance Global Partners Hires James Molloy

A.G.P./Alliance Global Partners has hired James Molloy as Managing Director and Biotechnology & Specialty Pharmaceuticals Equity Research Analyst.

Jim provides coverage of companies in several therapeutic categories in the biotechnology and pharmaceuticals sector, with a focus on immuno-oncology, central nervous system, cardiovascular, and anti-infective disorders. Prior to A.G.P., Jim was a Managing Director, Biotechnology and Specialty Pharmaceuticals Equity Research Analyst at Laidlaw Capital Markets, Janney Montgomery Scott, Senior Analyst at ThinkEquity Partners, and a Vice President of Equity Research at Oppenheimer and Company.

Jim has almost two decades of experience as a Senior Analyst covering both the mid-capitalization and emerging biotechnology and pharmaceutical sectors. He began his career as one of the first three analysts at Leerink Partners in Boston. He earned an MBA from the FW Olin Graduate School of Business at Babson College, and a BA from the University of Colorado, Boulder.

A.G.P. Executive Chairman Phil Michals noted: “We are very fortunate to have Jim join our team. He really understands this highly complex and constantly evolving space, and he has great relationships in the industry.”